Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
16.42
+0.06 (0.37%)
Yopilishda: May 12, 2026, 4:00 PM EDT
16.55
+0.13 (0.76%)
Bozor oldidan: May 13, 2026, 5:00 AM EDT
Takeda Pharmaceutical Company Limited Yaponiyada va xalqaro miqyosda farmatsevtika mahsulotlarini tadqiq qilish, ishlab chiqish, ishlab chiqarish, marketing va litsenziyalash bilan shug'ullanadi. Kompaniya gastroenterologiya, kam uchraydigan kasalliklar, plazmadan olingan terapiyalar, immunologiya, onkologiya va nevrologiya sohalarida farmatsevtika mahsulotlarini taklif etadi. Kompaniya o'z mahsulotlarini Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA va Alunbrig brendlari ostida taqdim etadi. Kompaniya BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme va Kamada bilan litsenziyalash shartnomalariga ega; Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Kioto universiteti (CiRA) iPS hujayra tadqiqotlari markazi va Charles River Laboratories bilan hamkorlik qiladi; Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center va Teva Pharmaceutical Industries bilan litsenziyalash shartnomasiga ega; Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics va Ovid Therapeutics Inc. bilan hamkorlik va litsenziyalash shartnomasiga ega; va ZEDIRA GmbH va Dr. Falk Pharma GmbH bilan hamkorlik qiladi. Kompaniya Crescendo Biologics bilan ilmiy-tadqiqot hamkorligi va litsenziyalash shartnomasiga ega. Kompaniya 1781-yilda tashkil etilgan va uning bosh qarorgohi Yaponiyaning Tokio shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrew S. Plump M.D., Ph.D. | President of Research & Development and Representative Director |
| Dr. Seigo Izumo | Chair of Management Board |
| Michael Fox | Chief Operating Officer |
| Mr. Christophe P. Weber | President, CEO & Representative Director |
| Mr. Gabriele Ricci | Chief Data & Technology Officer |
| Mr. Haruhiko Hirate | Member of Management Board |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-30 | 6-K | form6k_033026.htm |
| 2026-03-26 | 6-K | form6k_032626.htm |
| 2026-03-25 | 6-K | form6k_032526.htm |
| 2026-03-02 | 6-K | form6k_030226.htm |
| 2026-02-10 | 6-K | form6k_021026.htm |
| 2026-01-29 | 6-K | form6k_012926.htm |
| 2025-12-18 | 6-K | form6k_121825.htm |
| 2025-12-08 | 6-K | form6k_120825.htm |
| 2025-11-28 | 6-K | form6k_112825.htm |
| 2025-10-30 | 6-K | form6k-1_103025.htm |
| Mr. Iwaaki Taniguchi | Senior Vice President of Corporate Finance & Controlling Department |
| Mr. Milano Furuta | CFO & Director |
| Mr. Salvatore Alesci M.D., Ph.D. | Member of Management Board and Head of R&D Global Science & Biomedical Policy |
| Norimasa Takeda | Chief Accounting Officer & Corporate Controller |